Salvo launches first-ever RPM enablement for GI chronic conditions

In 2022 alone, the Remote Patient Monitoring (RPM) market grew to over $50 billion with the market set to exceed $175 billion by the year 2027.¹ In recent years, numerous medical studies have concluded better health outcomes and lower costs as a result of RPM programs.²  For providers and payers, treatment plans consisting of RPM for conditions such as diabetes, hypertension, congestive heart failure, and COPD have seen massive improvements in clinical outcomes while yielding cost-savings, and yet RPM had yet to be offered in GI…until now.

Today, Salvo Health announces the first-ever RPM offering for chronic GI conditions, including IBS, GERD/reflux, dyspepsia, Celiac, SIBO, and more. This new offering seeks to not only optimize better clinical outcomes for patients but increase practice reach and annual revenue for participating partners.‍

What to Expect‍

The Salvo Health GI RPM offering is a white-label/co-branded service offered through local GI practices and GI departments at hospital systems.  Participating, in-person GIs maintain current patient-provider relationships (including billing), while allowing Salvo to provide additional staffing, technology, home medical devices, and digital content - under the direct supervision of the GI partner.

Through this offering, our Salvo Health clinical team will: 

1. Utilize an FDA-cleared Class II mobile EKG device to monitor heart rate variability (HRV) in patients
2. Apply daily reporting and Salvo Health’s supplemental resources and tools and enable Care Teams to help patients better manage symptoms and avoid escalation into larger and more expensive problems, such as ER / urgent care visits or admissions common among sufferers
3. Leverage our app-based platform to provide patients with daily access to clinical support when reporting exacerbated symptoms and flare-ups; when patients are not improving, RPM teams escalate to the supervising physician for treatment adjustments
4. Introduce new billings of $260,000+ per annum per physician (assuming 150+ active patients enrolled monthly); collectively, bookings can reach millions for larger practices or GI divisions - all without the need for new in-house staff through leveraging Salvo’s staffing and platform  

Beyond Monitoring– A Comprehensive Program

‍Central to our RPM program offering is the belief that monitoring alone is insufficient to drive better outcomes. Our comprehensive approach pairs RPM enablement with intensive, evidence-based practices in behavior change, nutrition, GI-directed psychology, and daily symptom tracking to equip patients with the means to manage symptoms and stress responses.  

{{cta-1}}

Innovation for Patients & Providers Alike

1. Our program works for patients. Initial cohorts have seen 97% of patients report material symptom improvement after 4-12+ weeks of treatment, among those who reported severe symptoms at intake. 
2. Our patients are engaged. The average patient opens our mobile app daily with 80% participating in symptom and adherence tracking ("Gut Check") at least 2x a week over the course of their active treatment program.
3. RPM optimizes your reach. Ultimately, RPM enables physician practices to improve care while increasing profitability and freeing specialist physicians to practice at the top of their license. 

Studies show increases in HRV over time are closely associated with improved nutrition and psychological health, both tied closely to GI symptoms mediated by the Vagus Nerve³ while HRV tends to run lower in those with IBD and IBS symptoms.⁴ In addition, gut health problems have been tightly linked to anxiety and depression,⁵ in a vicious circle of cause and effect, with studies showing lower HRV prevalent in patients with anxiety symptoms.⁶

‍
By monitoring daily HRV over a period of months while recording adherence to nutrition, lifestyle, and behavior changes, providers can more accurately track improvement between physical and psychological symptoms plaguing many chronic GI sufferers to inform treatment plan adjustments and service better clinical outcomes. In addition, as a recent study noted, "It is advisable to include HRV measurements as a measure of the effectiveness of interventions in IBS therapy, and to assess autonomic changes as a moderator of the effectiveness of IBS therapy.

If you are a GI practice or health system GI division interested in learning more about leveraging Salvo’s provider enablement, please see our Provider page or reach out to partnerships@salvohealth.com. 

‍
‍Salvo Health is backed by a $10.5 million investment from the investors and founders behind such innovative health tech companies as Livongo, Tia, Forward, Ginger, Ro, and others. For more information on the company, please see our About Us.